跳至主要内容
临床试验/TCTR20230330010
TCTR20230330010已完成2 期

An open-label randomized controlled trial of curcumin versus standard dose of omeprazole in treatment of gastroesophageal reflux disease

Department of medicine, Phramongkutklao Hospital0 个研究点目标入组 62 人开始时间: 2023年3月30日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
62

研究概览

简要总结

Curcumin 2000 mg daily can significantly improves GERD symptoms and frequency significantly without worsening GERD symptoms. However, comparing these 2 parameters between curcumin and standard omeprazole treatment does not shows statistically significant difference.

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 65 Years(—)
性别
All

入选标准

  • patients who were diagnosed with gastroesophageal reflux disease (GERD) according to the Thailand GERD guideline 2020

排除标准

  • 1 patients presenting with alarm features such as dysphagia, gastrointestinal bleeding, anemia, involuntary weight loss, recurrent vomiting and odynophagia
  • 2 pregnant women or women who planned to become pregnant during the study
  • 3 patients previously diagnosed with esophageal stricture, esophageal cancer, irritable bowel diseases, hepatobiliary tract obstruction, refractory GERD
  • 4 allergy to omeprazole or curcumin
  • 5 unable to read and write in Thai language

研究者

相似试验